Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8+ T Cell Changes During Peg-IFN-α vs Nucleoside Analogues in Chronic Hepatitis B
NCT03209037Phase 4Unknown
- Sponsor
- Beijing Ditan Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2017
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Changes of CD8+ T Cells Frequency and Function at 24 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03209037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209037.